The Neuropeptide
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa is a peptide derivative of angiotensin IV developed by researchers at Washington State University. In preclinical studies, it demonstrated extraordinary potency in enhancing synaptic connectivity and cognitive function. It is estimated to be 10 million times more potent than BDNF at promoting the formation of new synaptic connections, making it one of the most potent cognitive-enhancing compounds ever identified in research.
Dihexa enhances cognitive function by promoting the formation of new synaptic connections (synaptogenesis) through activation of the hepatocyte growth factor (HGF)/c-Met receptor system. This is a fundamentally different pathway from other nootropic peptides.
Activates the HGF/c-Met receptor system, triggering powerful synaptogenic (new synapse formation) signaling in the brain.
Promotes neurite outgrowth and dendritic spine formation, physically creating new neural connections that underpin learning and memory.
Resists degradation by peptidases, providing sustained activity at the synaptic level despite its small molecular size.
Crosses the blood-brain barrier more effectively than many neuropeptides, allowing systemic administration to reach brain targets.
Preclinical studies show dramatic improvements in memory, learning, and cognitive function through enhanced synaptic connectivity.
Promotes the physical creation of new neural connections at extraordinary potency, potentially supporting recovery from cognitive decline.
Animal studies demonstrate significant improvements in both short-term and long-term memory formation and recall.
The HGF/c-Met pathway is involved in neuronal survival and protection, suggesting potential benefits beyond cognitive enhancement.
Dihexa was found to be approximately 10 million times more potent than BDNF in promoting new synaptic connections in hippocampal neuron cultures.
In scopolamine-induced cognitive impairment models, Dihexa fully restored learning and memory performance through HGF/c-Met pathway activation.
Dihexa demonstrated oral bioavailability and ability to cross the blood-brain barrier, producing cognitive enhancement in aging animal models.
Dihexa is a relatively new research compound with LIMITED safety data. While preclinical studies show promising cognitive effects, human clinical trials have not been completed. Its extraordinary potency warrants caution and strict physician supervision. This is among the least clinically validated compounds in this library.
Research Status
Dihexa has extraordinary preclinical data from Washington State University. However, human clinical trials are limited and the compound is still in early research stages. The gap between its remarkable preclinical potency and clinical validation represents both its promise and its current limitation.
Regulatory Note
Dihexa is not FDA-approved and is classified as a research compound. Its availability is limited and it should only be obtained through legitimate research channels or compounding pharmacies under physician supervision.